Zoetis Q1 Earnings: Missed Estimates and Mixed Trends Ahead

ZTS reported a disappointing first quarter on May 7, 2026, with revenue of $2.26 billion missing analyst estimates of $2.31 billion by 2.1%, and adjusted EPS of $1.53 falling short of the $1.62 consensus estimate by 5.3%. Sales grew just 1.9% year-over-year as the company's flagship companion animal segment came under pressure from a notably more price-sensitive pet owner base.

The U.S. segment bore the brunt of the weakness, with revenue declining 8% to $1.1 billion as companion animal product sales dropped 11%. Key products including the dermatology franchise and Simparica Trio faced softening demand and intensifying competition. Management acknowledged that the first quarter "unfolded in a more challenging operating environment than anticipated," with declining veterinary visit rates reducing demand for premium innovative products across the portfolio.

The earnings miss forced a meaningful guidance cut. Zoetis lowered its full-year 2026 revenue guidance to $9.82 billion at the midpoint, down from prior guidance of $9.93 billion, and trimmed adjusted EPS guidance to $6.93 at the midpoint, a 1.8% reduction. The stock dropped 13% to $96.81 on the news, erasing over a year's worth of gains in a single session and raising investor questions about whether structural headwinds in U.S. companion animal spending represent a temporary cyclical softening or a more durable shift.

Related Stocks

• ZTS